Riociguat

From HOP house of papers
Jump to: navigation, search

search term via moremed.org '
Riociguat

Contents

Core OA papers on Riociguat

Journal article, free access
GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2015. Riociguat: Something new in pulmonary hypertension therapeutics? Extract PDF direct
Journal article, free access
GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2013. Riociguat for the treatment of pulmonary arterial hypertension Extract PDF direct
Journal article, free access
GET 2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Extract PDF direct
Journal Paper, restricted access
GET 2014. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension Extract PDF direct

                                            

General outline of Pulmonary Hypertension

Journal article, free access
GET 2013. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2015. Medical treatment update on pulmonary arterial hypertension Extract PDF direct
Journal article, free access
GET 2015. The molecular targets of approved treatments for pulmonary arterial hypertension Extract PDF direct
Journal article, free access
GET 2015. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2014. Drug Therapy for Chronic Thromboembolic Pulmonary Hypertension: A Review of the Comparative Clinical Effectiveness Extract PDF direct
Journal article, free access
GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension Extract PDF direct
Journal article, free access
GET 2013. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Extract PDF direct
Journal article, free access
GET 2014. Respiratory review of 2014: pulmonary thromboembolism Extract PDF direct
Journal article, free access
GET 2014. Novel and emerging therapies for pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy Extract PDF direct
Journal Paper, restricted access
GET 2015. Pulmonary arterial hypertension: a review in pharmacotherapy Extract PDF direct

Mechanism of action

Journal article, free access
GET 2010. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Extract PDF direct
Journal article, free access
GET 2009. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Extract PDF direct
Journal article, free access
GET 2008. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Extract PDF direct
Journal Paper, restricted access
GET 2013. The chemistry and biology of soluble guanylate cyclase stimulators and activators Extract PDF direct
Journal Paper, restricted access
GET 2009. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension Extract PDF direct
Journal Paper, restricted access
GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct
Journal Paper, restricted access
GET 2009. NO-independent, haem-dependent soluble guanylate cyclase stimulators Extract [{| class="wikitable"; style="border: 1pt"
Journal Paper, restricted access
GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct
PDF direct]

|}


                                            


Some trials

Journal Paper, restricted access
GET 2015. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Extract PDF direct
Journal Paper, restricted access
GET 2015. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Extract PDF direct
Journal article, free access
GET 2014. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study Extract PDF direct
Journal article, free access
GET 2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema Extract PDF direct
Journal article, free access
GET 2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Extract PDF direct
Journal article, free access
GET 2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct
Journal article, free access
GET 2013. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT Extract PDF direct
Journal article, free access
GET 2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study Extract PDF direct
Journal article, free access
GET 2015. Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food Extract [ PDF direct]
Journal article, free access
GET 2015. The sGC-stimulator Riociguat for the treatment of Raynaud s phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT) Extract [ PDF direct]

                                            

Nephrology-related data

Journal Paper, restricted access
GET 2013. The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis Extract PDF direct
Journal Paper, restricted access
GET 2015. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies Extract PDF direct
Journal article, free access
GET 2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence Extract PDF direct
Journal article, free access
GET 2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Extract PDF direct
Journal Paper, restricted access
GET 2010. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models Extract PDF direct

Article Collections

Weblink noncommercial '
Congress Abstracts on Guanylate Cyclase Stimulation 2015 Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Links

Weblink noncommercial '
Heise-Technol-Rev. Bericht zur Ehrung der Entwickler
Wikipedia
en-wiki
de-wiki

Books

Personal tools
Namespaces
Variants
Actions
Navigation
Toolbox
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis